Effects of rifampicin (600 mg repeated oral dose) co-administration on the pharmacokinetics of roflumilast (500 μg single oral dose) and roflumilast N-oxide. A CY3A4 inducer study in healthy male subjects
Study Complete
Official Title
*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
-
Sex
Male
Actual Enrollment
16
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Sept 2004
Primary Completion Date: -
Study Completion Date: 01 Oct 2004
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2016 by Takeda
Sponsors
Takeda
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
